The Dupixent® lawsuit centers on claims that the drug, commonly prescribed for eczema, asthma, and nasal polyps, may be linked to Cutaneous T-Cell Lymphoma (CTCL) — a rare and serious form of skin cancer. Plaintiffs allege that the manufacturers failed to adequately warn patients and doctors about the potential risk of CTCL associated with Dupixent (dupilumab). Some patients experienced worsening skin conditions or delayed cancer diagnoses, as CTCL can mimic eczema symptoms. Lawsuits seek compensation for medical expenses, emotional distress, and long-term health impacts. If you were diagnosed with CTCL after using Dupixent, you may qualify for legal action.

Dupixent® (dupilumab) Lawsuit

Last Updated: July 29, 2025

Have you been prescribed Dupixent (dupilumab) and later diagnosed with Cutaneous T‑Cell Lymphoma (CTCL)? You may be eligible to take legal action.

🔍 Recent Developments

• New Dupixent-CTCL claims filed by patients who developed rare lymphomas after treatment.

• Regulators and courts pressed to evaluate whether the manufacturer adequately warned about CTCL risk.

• Attorneys focusing on whether internal safety data indicated potential lymphoma risk before public release.

Complete the form to see if you may qualify and take the first step toward potential recovery.

What’s the Case About?

Lawsuits allege that Dupixent, a biologic used to treat eczema, asthma, and nasal polyps, may be associated with the development or exacerbation of CTCL, a rare skin lymphoma. Plaintiffs argue the manufacturer failed to provide early or adequate warnings, despite signals from clinical studies and pharmacovigilance reports.

Who May Qualify?

• Individuals treated with Dupixent and later diagnosed with CTCL

• Patients with medical records confirming diagnosis

• Those who experienced worsening skin conditions or delayed diagnosis linked to Dupixent exposure

How It Works: Legal Process

Why Legal Representation Matters

• Medical Evidence Required: Links between CTCL and Dupixent rely on dermatology and pathology records.

• Full Compensation: You may be entitled to damages for medical bills, emotional distress, and lost wages.

• Statute of Limitations: Acting early is critical. Filing deadlines vary by state and begin when you knew—or should’ve known—about CTCL.

About Dupixent (dupilumab)

Dupilumab (Dupixent®) is an injectable biologic medicine approved for treating moderate to severe atopic dermatitis (eczema), certain types of asthma, and chronic rhinosinusitis with nasal polyps. Although clinical trials initially showed efficacy and safety, recent reports have raised concerns about possible CTCL risk in a small subset of patients.

Health Conditions Tied to This Lawsuit

• Cutaneous T‑Cell Lymphoma (CTCL) — rare lymphoma affecting skin, sometimes misdiagnosed as eczema

• Cases where skin disease worsened or progressed after Dupixent use

• Delayed lymphoma detection possibly masked by eczema symptoms

Why Act Now

Like AFFF litigation, pharmaceutical cases have court timeline phases, evidentiary deadlines, and case selection periods. Early involvement can strengthen your claims and preservation of medical evidence dramatically improves your ability to recover compensation for your suffering.

Your Next Step

If you or a loved one used Dupixent and were later diagnosed with CTCL, you could qualify for compensation. Please fill out our quick eligibility review form. If you meet the criteria, we'll connect you with trusted attorneys who specialize in Dupixent litigation.

Complete the form to see if you may qualify and take the first step toward potential recovery.